BioPharm
International's Advances in Vaccine Development and Manufacturing supplement will provide practical examples of how manufacturers are addressing ongoing challenges and taking advantage of new opportunities. Vaccine manufacturers are seeking more robust processing methods, and even platforms, along with better vaccine characterization. At the same time, new developments present new opportunities in how and where vaccines are made-such as in small, disposables-based plants in emerging markets or regional facilities in developed countries for autologous therapeutic vaccines-and how they are delivered to patients, including improved stability and formulations that obviate the need for cold-chain storage. The supplement will be distributed to the entire BioPharm International circulation as a pull-out section of the January 2011 issue.
>>> The ad close for this supplement issue is
December 10 <<<
>>> The material due date is December 18
<<<
|
ADVANCES IN VACCINE DEVELOPMENT AND MANUFACTURING EDITORIAL HIGHLIGHTS |
-
Evolution of Live-Attenuated HIV vaccines
-
Virosomes: A Novel Strategy For Drug Delivery and Targeting
-
Regulatory Considerations for Vaccine Comparability
-
Q&A with Nova Laboratories
Contact Your Representative
Pat Venezia Jr.
732-346-3011
pvenezia@advanstar.com
James Gray
44(0)1244 393101
jgray@advanstar.com
| 
